BioNTech SE (BNTX) revenue breakdown
By product, COVID-19 vaccine revenues is the largest at 70% of fiscal 2025 revenue; Other revenues grew fastest, 17% a year over 3 years.
By region, United States is the largest at 63% of fiscal 2025 revenue; Ireland grew fastest, 22% a year over 2 years.
Revenue by product
Fiscal years, as BioNTech SE reports them in its 10-K filings; fiscal 2025 total $2.9B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 vaccine revenues | — | — | — | — | — | $17.1B | $3.8B | $2.4B | $2.0B | 70% |
| Revenues from out-licensing | — | — | — | — | — | — | — | — | $613M | 21% |
| Other revenues | — | — | — | — | — | $165M | $43M | $319M | $262M | 9% |
| Commercial revenues | $19M | $26M | $24M | $304M | $18.9B | — | — | — | — | — |
| Research & development revenues | $42M | $102M | $84M | $179M | $103M | — | — | — | — | — |
Revenue by region
Fiscal years, as BioNTech SE reports them in its 10-K filings; fiscal 2025 total $2.9B.
| Regions | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| United States | $12.7B | $3.0B | $1.8B | $1.8B | 63% |
| Germany | $3.0B | $483M | $707M | $759M | 26% |
| Ireland | — | $204M | $178M | $305M | 11% |
| Rest of the World | $1.6B | $122M | $19M | $11M | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BNTX.
Open BNTX in InvestinglyQuestions
Where does BioNTech SE make its money?
In fiscal 2025, by product: COVID-19 vaccine revenues $2.0B, Revenues from out-licensing $613M, Other revenues $262M.
From BioNTech SE's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.